PBAC's latest decision on Human menopausal gonadotrophin: Recommended (2022). Considered for Treatment of infertility in anovulatory infertility (including polycystic ovarian disease) unresponsive to clomiphene citrate, and for controlled ovarian hyperstimulation to induce development of multiple follicles for assisted reproductive technologies (IVF/ET, GIFT, ICSI).
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2012
Submissions
3
2012 → 2022
Eligible population
Women receiving medical services for assisted reproductive technology (IVF/ET, GIFT, ICSI) under Medicare items 13200, 13201, 13202 or 13203, including those with anovulatory infertility unresponsive to clomiphene citrate.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
human menopausal gonadotrophin powder for injection (PFI) forms
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC assessed on cost-minimisation basis against existing PFI forms.
Submission history
Mar 2012: Recommended with restriction · Restricted